Literature DB >> 30058921

Advances in our understanding of the prognosis of adrenal incidentaloma.

Iain Mackay1, Sebastian Aspinall2.   

Abstract

INTRODUCTION: As cross-sectional abdominal imaging is used increasingly, adrenal incidentaloma (AI) are being found frequently and present a clinical dilemma. The vast majority are benign and non-functioning, but a minority represent incidentally found functional or malignant tumours. In this review we summarise the current clinical, biochemical and radiological investigation of AI and discuss recent advances that differentiate clinically inconsequential lesions from functional and/or malignant AI. Areas covered: Prevalence, natural history, biochemical and radiological assessment, indications for surgery and surgical provision. Expert commentary: Well established work-up of AI usually enables benign, non-functioning lesions to be differentiated from functioning and/or malignant AI. In indeterminate lesions recent advances in work-up such as urine steroid profiles measured by gas chromatography /mass spectrometry and functional imaging with 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) in addition to standard investigations have improved characterisation of these lesions. The management of AI showing mild autonomous hypercortisolism without overt features of Cushing's syndrome remains controversial and is discussed in this review.

Entities:  

Keywords:  Adrenal gland; Cushing’s syndrome; adrenal adenoma; adrenalectomy; adrenocortical carcinoma; computed tomography; incidentaloma; magnetic resonance imaging; phaeochromocytoma; primary hyperaldosteronism

Year:  2016        PMID: 30058921     DOI: 10.1080/17446651.2016.1233055

Source DB:  PubMed          Journal:  Expert Rev Endocrinol Metab        ISSN: 1744-6651


  1 in total

Review 1.  Primary antiphospholipid syndrome, Addison disease, and adrenal incidentaloma.

Authors:  Gabriela Medina; María Pilar Jiménez-Arellano; Andrés Muñoz-Solís; Erick Servín-Torres; Pablo Ramírez-Mendoza; Luis J Jara
Journal:  Clin Rheumatol       Date:  2020-03-07       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.